Monday, November 21, 2005

Aromasin Approved by the FDA for Post-menopausal Women with Early-Stage ER+ Breast Cancer

The U.S.F.DA. has approved Aromasin (chemical name: exemestane) to treat post-menopausal women with hormone-receptor-positive, early-stage breast cancer after two to three years of tamoxifen (for a total of five years of hormonal therapy). Aromatase inhibitors reduce the amount of estrogen available to stimulate the growth of hormone-receptor-positive breast cancer. After menopause, most of the body's estrogen is made from another hormone, androgen. Aromatase inhibitors stop the enzyme called aromatase from turning androgen into estrogen. See here for an explanation of Aromatase Inhibitors.


Post a Comment

<< Home

/* WebRing Code */